We have found that a small number of purified Th2-biased Aβ-specific T cells are sufficient to provide profound cognitive and pathological benefits in an APP+PS1 mouse model for Alzheimer's disease. Six weeks after receiving T cell infusions, cognitively-impaired mice performed significantly better in working memory tasks, which correlated with higher plasma levels of soluble Aβ. Pathological analysis of the hippocampus revealed a 30% decrease of plaque-associated microglia and less vascular amyloidosis in T cell treated mice. The infusion of Aβ-specific Th2 cells also reduced plasma levels of IFN-γ, TNF-α, GM-CSF, IL-2 and IL-4, which are elevated in untreated APP+PS1 mice. No significant immune cell infiltration and no anti-Abeta antibody titers occurred in the T cell treated mice. These results demonstrate that Aβ-specific Th2 cells are sufficient to reverse cognitive impairment and provide multiple pathological benefits in an Alzheimer's mouse model.
Introduction
The elevation of immune responses to amyloid-beta (Aβ) underlies several promising therapeutic strategies for the treatment of Alzheimer's disease (AD). Vaccinations with Aβ plus adjuvant trigger adaptive immune responses that improve cognitive performance and lessen brain pathology in mouse models of AD (Schenk et al., 1999; Morgan et al., 2000) . A clinical trial that vaccinated patients with Aβ 1-42 (AN1792) was initially promising, but was halted after several patients developed aseptic meningoencephalitis. Subsequent analysis revealed that brain inflammation in those patients may have resulted from robust inflammatory T helper type-1 (Th1) responses due to the inclusion of polysorbate-80 in the vaccine formula (Orgogozo et al., 2003) . Since then, many immunotherapeutic strategies have tried to limit T cell responses by employing anti-Aβ-specific monoclonal antibodies to provide passive immunity (Bayer et al., 2005) . Although large doses of these antibodies are used, beneficial effects result from an ill-defined peripheral mechanism as antibodies are largely excluded from the brain parenchyma by the blood brain barrier (BBB). Recently, we have reported that non-inflammatory T cell responses to Aβ may provide long-term beneficial effects without encephalitogenic side-effects (Ethell et al., 2006) . Within the brain of Alzheimer's patients, inflammatory responses associated with amyloid plaques consist of local innate immune mediators such as reactive astrocytes and activated microglia. The absence of activated T cells, neutrophils, and immunoglobulins within the parenchyma suggest that chronic AD pathology has minimal involvement by adaptive immune responders such as inflammatory (Th1) or allergy (Th2) mediating T cells. We previously reported that Aβ-specific T cells can reverse cognitive impairment and provide multiple pathological benefits when transferred into the APP+PS1 mouse model, without significant infiltration of the CNS (Ethell et al., 2006) . These beneficial effects include the restoration of near normal working memory and fewer plaque-associated microglia in the hippocampus. Infusions containing both Th1 and Th2 cells were beneficial, while those biased toward Th1 or depleted of CD4 + T cells were not. We also found that infusions from mice that were vaccinated with an exogenous antigen (i.e. chicken ovalbumin) did not provide any cognitive benefits, indicating the effects were antigenspecific. APP+PS1 mice treated with Aβ-specific T cells did not show any signs of immune cell infiltration within the CNS as seen in the AN1792 trial. These findings suggest that Aβ-specific effector T cells can improve cognitive performance and slow pathological progression in a mouse model for AD, and underscore that allergy-mediating Th2 cells may be more relevant than inflammation-mediating Th1 cells for these benefits.
Here we report that purified Aβ-specific Th2 cells are necessary and sufficient to provide cognitive and pathological benefits in the 
